Sean: "Results published in HIV Clinical Trials (2018) showed that in the CD01 study 23 out of 41 participants (56.1%) maintained Viral Suppression throughout the (12) week Monotheraphy treatment phase. (18) participants did Not maintain suppression during the treatment phase

Read More: https://investorshangout.com/post/view?id=660...z89hmSGqW0

Any of my betters care to discuss this apparent ambvalence in LL potency? TIA.